About Myosin regulatory light chain 2, ventricular/cardiac muscle isoform
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MYL2) is a protein
from Homo sapiens identified by UniProt accession
P10916, 166 residues long.
MolForge cross-references it against 0 known binders and
269 disease associations.
Target properties
| Protein name | Myosin regulatory light chain 2, ventricular/cardiac muscle isoform |
|---|
| UniProt accession | P10916 |
|---|
| Gene | MYL2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 166 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (269)
Diseases linked to this target (Open Targets).
- hypertrophic cardiomyopathy 10 · score 0.81
- Rare familial disorder with hypertrophic cardiomyopathy · score 0.76
- hypertrophic cardiomyopathy · score 0.74
- cardiomyopathy · score 0.52
- congenital fiber-type disproportion myopathy · score 0.50
- Abnormality of the cardiovascular system · score 0.47
- familial hypertrophic cardiomyopathy · score 0.47
- congenital heart disease · score 0.42
- urate measurement · score 0.38
- cardiovascular disease · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P10916-F1 | alphafold | PREDICTED | 83.51 | — |
Amino-acid sequence (166 residues)
MAPKKAKKRA GGANSNVFSM FEQTQIQEFK EAFTIMDQNR DGFIDKNDLR DTFAALGRVN VKNEEIDEMI KEAPGPINFT VFLTMFGEKL KGADPEETIL NAFKVFDPEG KGVLKADYVR EMLTTQAERF SKEEVDQMFA AFPPDVTGNL DYKNLVHIIT HGEEKD
Explore Myosin regulatory light chain 2, ventricular/cardiac muscle isoform with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets